Tumours carrying cMet amplification were highly positive for phospho‐cMet after vehicle control treatment, while 5‐day treatment with Tepotinib impaired the in vivo phosphorylation of cMet (Fig 5C). The gene discussed is MET; the disease is neoplasm.